Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
102 hedge funds and large institutions have $245M invested in Achillion Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 46 increasing their positions, 26 reducing their positions, and 37 closing their positions.
476% more call options, than puts
Call options by funds: $59.1M | Put options by funds: $10.3M
77% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 26
16% less funds holding
Funds holding: 122 → 102 (-20)
54% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 37
65% less capital invested
Capital invested by funds: $707M → $245M (-$462M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$48M |
| 2 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$8.23M |
| 3 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
+$7.71M |
| 4 |
State Street
Boston,
Massachusetts
|
+$6.05M |
| 5 |
QF
QVT Financial
New York
|
+$5.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$35M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$13.5M |
| 3 |
DM
Deerfield Management
New York
|
-$13.3M |
| 4 |
Jennison Associates
New York
|
-$11.3M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$8.84M |
ACHN Hedge Fund Activity: Q3 2013 in Review
102 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q3 2013, worth a combined $245M — down 65% from $707M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of ACHN and 17 opened new positions — a net loss of 20 holders — while 26 trimmed existing stakes and 46 added.
The largest buyer was RA Capital Management, adding an estimated $48M. The largest seller was Fidelity Investments, cutting an estimated $35M.
- 102 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q3 2013, down from 122 in Q2 2013.
- Funds reported $245M of Achillion Pharmaceuticals stock for Q3 2013, down 65% quarter-over-quarter.
- 17 funds opened new Achillion Pharmaceuticals positions in Q3 2013 and 37 closed out, a net change of -20 holders.
- The largest Achillion Pharmaceuticals buyer in Q3 2013 was RA Capital Management, an estimated $48M added.
- The largest Achillion Pharmaceuticals seller in Q3 2013 was Fidelity Investments, an estimated $35M sold.
Based on aggregated 13F filings for Q3 2013.